Stratify Genomics was founded by a leading urologist who became increasingly concerned about the controversy surrounding PSA screening which led to delayed diagnosis and increase in incurable disease in his patients. Stratify Genomics is focused on a solution designed to curb this disturbing trend.
The Prompt Prostate Genetic Score is a major advancement in defining risk for prostate cancer. This simple test, performed with a cheek swab sample, at any age, can help identify those high-risk men who may benefit most from prostate cancer screening and possibly even strategies to prevent prostate cancer.
Stratify is dedicated to advancing the knowledge of genetic predisposition to cancer and other diseases so that patients and physicians can screen more effectively and efficiently.